Business
Conavi Medical Announces New Grant of Stock Options
TORONTO, June 03, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTCQB: CNVIF) (...
About this update from Conavi Medical Corp.
[{"type":"text","content":"Conavi Medical Announces New Grant of Stock Options\n\n\n\n TORONTO, June 03, 2025 (GLOBE NEWSWIRE) -- Conavi Medical Corp. (TSXV: CNVI; OTCQB: CNVIF) (“\n \n Conavi Medical\n \n ” or the “\n \n Company\n \n ”), announced that its board of directors (the “Board”) has approved grants of stock options (the “Stock Options”) Plan on June 2, 2025 pursuant to the terms of its Omnibus Equity Incentive Plan. A total of 5,849,098 Stock Options have been awarded to directors, officers, employees and consultants of the Company. The Stock Options are exercisable at a price of $0.39 CAD per share (being the closing price of the Company’s shares on the TSXV on June 2, 2025) for a period of 10 years from the date of the grant.\n \n\n 1,930,172 of such Stock Options were allocated as follows to the Company’s independent directors: 341,624 Stock Options to Anthony Giovinazzo, 341,624 Stock Options to Cathy Steiner, 330,807 Stock Options to Robert Mitchell, 358,242 Stock Options to Susan Allen and 557,875 Stock Options to Aaron Davidson.\n \n\n 3,581,216 of such Stock Options were allocated as follows to the Company’s officers: 298,413 Stock Options to Travis More, 266,863 Stock Options to Amandeep Thind, 393,924 Stock Options to Sumeet Dham, 425,000 Stock Options to Stefano Picone and 2,197,646 Stock Options to Thomas Looby.\n \n\n The remaining Stock Options were granted to other employees and consultants.\n \n\n The Company also announced minor changes to the composition of its Audit Committee, with Board Chair Aaron Davidson having stepped down from the Audit Committee and independent directors Susan Allen, Cathy Steiner and Robert Mitchell continuing to serve.\n \n\n\n About Conavi Medical\n \n\n\n Conavi Medical is focused on designing, manufacturing, and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid™ System is the first system to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid System has 510(k) clearance from the U.S. Food and Drug Administration; and regulatory approval for clinical use from Health Canada, China’s National Medical Products Adm...